JP2022546400A5 - - Google Patents

Info

Publication number
JP2022546400A5
JP2022546400A5 JP2022513090A JP2022513090A JP2022546400A5 JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5 JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022513090 A JP2022513090 A JP 2022513090A JP 2022546400 A5 JP2022546400 A5 JP 2022546400A5
Authority
JP
Japan
Prior art keywords
pharmaceutical
liquid formulation
approximately
formulation according
stabilized liquid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022513090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022546400A (ja
JP7792137B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/058080 external-priority patent/WO2021038532A1/en
Publication of JP2022546400A publication Critical patent/JP2022546400A/ja
Publication of JP2022546400A5 publication Critical patent/JP2022546400A5/ja
Application granted granted Critical
Publication of JP7792137B2 publication Critical patent/JP7792137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022513090A 2019-08-30 2020-08-29 高濃度の薬理学的に活性な抗体の新規製剤 Active JP7792137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921035059 2019-08-30
IN201921035059 2019-08-30
PCT/IB2020/058080 WO2021038532A1 (en) 2019-08-30 2020-08-29 Novel formulation of highly concentrated pharmacologically active antibody

Publications (3)

Publication Number Publication Date
JP2022546400A JP2022546400A (ja) 2022-11-04
JP2022546400A5 true JP2022546400A5 (cg-RX-API-DMAC7.html) 2023-11-24
JP7792137B2 JP7792137B2 (ja) 2025-12-25

Family

ID=74684124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513090A Active JP7792137B2 (ja) 2019-08-30 2020-08-29 高濃度の薬理学的に活性な抗体の新規製剤

Country Status (7)

Country Link
US (2) US20220267473A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021497B1 (cg-RX-API-DMAC7.html)
JP (1) JP7792137B2 (cg-RX-API-DMAC7.html)
AU (1) AU2020337093B2 (cg-RX-API-DMAC7.html)
CA (1) CA3152838A1 (cg-RX-API-DMAC7.html)
ES (1) ES3071089T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021038532A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
CA3237624A1 (en) * 2023-07-28 2025-04-24 Genentech, Inc. NEW USES FOR OMALIZUMAB

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US20140186361A1 (en) * 2012-09-07 2014-07-03 Coherus Biosciences, Inc. Stable Aqueous Formulations of Adalimumab
PT1610820E (pt) * 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
CA2690382A1 (en) 2007-06-14 2008-12-24 Biogen Idec Ma Inc. Antibody formulations
SG10201500871TA (en) * 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
AR089434A1 (es) * 2011-12-23 2014-08-20 Genentech Inc Procedimiento para preparar formulaciones con alta concentracion de proteinas
KR20160105535A (ko) 2012-03-07 2016-09-06 카딜라 핼쓰캐어 리미티드 TNF-α 항체의 약제학적 제형
JP2016515120A (ja) 2013-03-15 2016-05-26 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. 抗アルファvベータ5抗体を用いた急性腎損傷の治療及び予防
RS57864B1 (sr) * 2013-06-17 2018-12-31 De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo Postupci za sprečavanje agregacije virusnih komponenti
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス,インコーポレーテッド アグリコシル化治療用抗体の製剤
US10994011B2 (en) 2015-12-18 2021-05-04 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human TSLP receptor antibody
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
US10646569B2 (en) * 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración

Similar Documents

Publication Publication Date Title
US12296008B2 (en) Pharmaceutical products and stable liquid compositions of IL-17 antibodies
JP7112327B2 (ja) ベバシズマブの緩衝された製剤
JP2023055780A5 (cg-RX-API-DMAC7.html)
JP7473603B2 (ja) 液体医薬組成物
JP2019536761A5 (cg-RX-API-DMAC7.html)
Hufnagel et al. Dry powders for inhalation containing monoclonal antibodies made by thin-film freeze-drying
JP2021155453A5 (cg-RX-API-DMAC7.html)
JP2022166006A5 (cg-RX-API-DMAC7.html)
JP2010500360A5 (cg-RX-API-DMAC7.html)
JP7089121B2 (ja) 高濃度の抗vegf抗体を含有するタンパク質溶液製剤
RU2012139181A (ru) Стабильная композиция, содержащая антитело
AR071852A1 (es) Formulacion farmaceutica de un anticuerpo frente a ox40l
JP2018512391A5 (cg-RX-API-DMAC7.html)
PE20091327A1 (es) Composicion farmaceutica que comprende anticuerpos monoclonales
JP2013500947A5 (cg-RX-API-DMAC7.html)
JP2013543505A5 (cg-RX-API-DMAC7.html)
HRP20250830T1 (hr) Farmaceutski pripravak s niskim ph koji sadrži konstrukte protutijela koja djeluju na t-stanice
MA62173B1 (fr) Formulations d'anticorps anti-rankl humains et leurs procédés d'utilisation
JP2016515124A5 (cg-RX-API-DMAC7.html)
JP2021521159A5 (cg-RX-API-DMAC7.html)
RU2011140498A (ru) Препарат антител
JP2021521171A5 (cg-RX-API-DMAC7.html)
CN107249639A (zh) 联用药物
RU2018129077A (ru) Стабильная фармацевтическая композиция
JP2021501213A5 (cg-RX-API-DMAC7.html)